Correlation Between Champions Oncology and Eupraxia Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Champions Oncology and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Champions Oncology and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Champions Oncology and Eupraxia Pharmaceuticals, you can compare the effects of market volatilities on Champions Oncology and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Champions Oncology with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Champions Oncology and Eupraxia Pharmaceuticals.

Diversification Opportunities for Champions Oncology and Eupraxia Pharmaceuticals

0.02

Correlation Coefficient

Champions Oncology  Eupraxia Pharmaceuticals

Significant diversification

The 3 months correlation between Champions and Eupraxia is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Champions Oncology and Eupraxia Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and Champions Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Champions Oncology are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of Champions Oncology i.e., Champions Oncology and Eupraxia Pharmaceuticals go up and down completely randomly.

Pair Corralation between Champions Oncology and Eupraxia Pharmaceuticals

Given the investment horizon of 90 days Champions Oncology is expected to under-perform the Eupraxia Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Champions Oncology is 1.02 times less risky than Eupraxia Pharmaceuticals. The stock trades about 0.0 of its potential returns per unit of risk. The Eupraxia Pharmaceuticals is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  313.00  in Eupraxia Pharmaceuticals on August 28, 2024 and sell it today you would lose (34.00) from holding Eupraxia Pharmaceuticals or give up 10.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	75.76%
Values	Daily Returns

Champions Oncology  vs.  Eupraxia Pharmaceuticals

Champions Oncology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Champions Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Champions Oncology is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors.

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eupraxia Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Eupraxia Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Pair Trading with Champions Oncology and Eupraxia Pharmaceuticals

The main advantage of trading using opposite Champions Oncology and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Champions Oncology position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.

The idea behind Champions Oncology and Eupraxia Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.